LiverTarget is an international research project targeted to cardiovascular and metabolic diseases. LiverTarget project has got 6 million euros funding from Horizon Europe program, and there are nine selected research centers and organizations from Europe. In addition to Finland there is top know-how from Denmark, Germany, The Netherlands, Greece, Italy and Portugal.
Background
Obesity, diabetes, non-alcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular disease (ASCVD), in turn, are highly prevalent devastating diseases of our times despite available medicines, accounting for more than one in two deaths worldwide.
RNA Therapeutics comprise a new rapidly expanding category of drugs including small interfering RNAs (siRNA) and messenger RNAs (mRNA) that have attracted tremendous interest recently due to their first in-class drug approvals and notable success of the mRNA vaccines in the clinic.
Goal
LiverTarget aims to develop and validate novel RNA inhibition and activation therapeutics against cardiovascular and metabolic diseases by targeting ceramide synthesis and/or inflammatory cascades in the liver.
Funding
Funding source
Horizon Europe (GA no 101057724)
Coordinating organisation
Tampere University
Co-operators
University of Milan
siTOOLs Biotech GmbH
University of Southern Denmark
Biomedical Research Foundation Academy of AthensLamdaz
Therapeutics
UMC Utrecht
AstraZeneca
Vector B2B